Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

azimexon

Azimexon (2-cyanaziridinyl-2-carbamoyl-aziridinyl-1-propane) is a derivative of 2-cyanaziridine. Immunostimulant which shows therapeutic effects in tumor models and experimental infections in vitro, enhancing T lymphocyte transformation and phagocytosis. The mode of action of azimexon is unknown. It has been suggested that azimexon may alkylate DNA. In cancer patients it increases leukocytosis, blood active T rosettes, T4/T8 ratio, and is used as an adjuvant to chemotherapy in the treatment of melanoma and myeloma.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:azimexone
Abbreviation:AZ
Code name:BM 12.531
BM12531
Chemical structure:2-aziridinecarboxamide, 1-[1-(2-cyano-1-aziridinyl)-1-methylethyl]
2-cyanaziridinyl-2-carbamoyl-aziridinyl-1-propane
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search